CCR5 targeted cell therapy for hiv and prevention of viral escape

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F15%3A00011365" target="_blank" >RIV/00023736:_____/15:00011365 - isvavai.cz</a>
Result on the web
<a href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84938412709&partnerID=40&md5=6cd513e3a564f72cbd80ee5b55d57fba" target="_blank" >http://www.scopus.com/inward/record.url?eid=2-s2.0-84938412709&partnerID=40&md5=6cd513e3a564f72cbd80ee5b55d57fba</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/v7082816" target="_blank" >10.3390/v7082816</a>

Result language
angličtina
Original language name
CCR5 targeted cell therapy for hiv and prevention of viral escape
Original language description
Allogeneic transplantation with CCR5-delta 32 (CCR5-d32) homozygous stem cells in an HIV infected individual in 2008, led to a sustained virus control and probably eradication of HIV. Since then there has been a high degree of interest to translate this approach to a wider population. There are two cellular ways to do this. The first one is to use a CCR5 negative cell source e.g., hematopoietic stem cells (HSC) to copy the initial finding. The second way is to knock down CCR5 expression by gene therapy. Currently, there are five promising techniques, three of which are presently being tested clinically. These techniques include zinc finger nucleases (ZFN), clustered regularly interspaced palindromic repeats/CRISPR-associated protein 9 nuclease (CRISPR/Cas9), transcription activator-like effectors nuclease (TALEN), short hairpin RNA (shRNA), and a ribozyme.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)